Graviton Biosciences partners with Prelude to drive study efficiency and data integrity in neurology clinical trial

Austin, TX – Prelude, an eClinical data management system, is announcing a successful partnership with Graviton Bioscience, a privately held biotechnology company, to deploy a new clinical study database supporting Graviton’s neurological clinical trial focused on Cerebral Cavernous Malformation (CCM). Prelude’s highly configurable solution and in-house, hands-on customer support was critical to addressing the unique challenges of Graviton’s study, including managing and analyzing MRI imaging data from sites across the world.

“Prelude’s tailored solution not only met but exceeded our expectations, providing a comprehensive, user-friendly database that streamlined the data management process and enhanced the integrity of our study,” said Jonathan Galindo, Senior Clinical Trial Manager at Graviton.

Project highlights as shared by the Graviton team:

• Innovative Problem Solving: Prelude delivered a customized solution to address the unique requirements of the study during the build phase. Their expertise ensured smooth integration of imaging data into the study framework.
• Exceptional Communication: Communication from Prelude’s dedicated project lead and CDMS builder was exemplary throughout the project. The team’s prompt and clear updates kept all stakeholders aligned and confident in the progress.
• Collaborative Approach: Prelude demonstrated a true spirit of collaboration, working closely with the Graviton team to ensure every detail of the solution met the specific requirements of the trial.
• Proactive Timeline Management: Prelude’s proactive approach to maintaining timelines was key to the project’s success. Their commitment to meeting deadlines ensured the trial stayed on track without compromising quality.

“We are proud to partner with Graviton Biosciences to support their critical work in neurology. Our flexible data management solution and hands-on support enabled a streamlined, high-integrity approach to their study, ensuring they could focus on advancing research without getting bogged down in the technology,” said Tommy Jackson, CEO of Prelude.

About Prelude

Prelude is a life science software company dedicated to advancing modern complex clinical research with tailored eClinical solutions and unmatched customer service. Our goal is to simplify the research process from study build to closeout, empowering our partners to make the world safer and healthier by accelerating the development of new medicines and devices.

Founded in 2003, Prelude created one of the first electronic data capture (EDC) systems designed to accommodate complex studies while delivering a simple, clean end user experience to sites and investigators. Today, Prelude offers a comprehensive suite of eClinical data management solutions including ePRO, eConsent, RTSM, etc., leveraged globally by leading research institutions such as Cornell University, Johns Hopkins University, Merck, Boehringer Ingelheim, and more.

Prelude prioritizes deep partnership with our customers, providing comprehensive in-house support and a fully configurable eClinical platform. For more information, please visit www.PreludeEDC.com.

About Graviton Bioscience Corporation

Graviton Bioscience Corporation is a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating CNS, autoimmune, fibrotic, and other serious diseases where ROCK2 and its other therapeutic compounds play a pivotal role in pathology.  Graviton’s first drug candidate GV101 is in clinical studies, with additional assets advancing through the preclinical pipeline.  Leading the company is Dr. Samuel Waksal, the founder and former Chairman and CEO of Kadmon Pharmaceuticals (acquired by Sanofi). Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx (NASDAQ: MGTX).  

For more information, please visit www.gravitoncorp.com